Internal Medicine Residency

References

• Mounsey A, Brendle DC, Flowers K. Oral vs. Intramuscular Vitamin B12 for Treating Vitamin B12 Deficiency. Am Fam Physician. 2022 Jun;105(6):663-664. PMID: 35713630.
• Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, McDowell I, Papaioannou A. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004655. doi: 10.1002/14651858.CD004655.pub2. Update in: Cochrane Database Syst Rev. 2018 Mar 15;3:CD004655. PMID: 16034940; PMCID: PMC5112015.
• Vitamin B12 Deficiency As a Cause of Hemolytic Anemia. Abstract published at Hospital Medicine 2012, April 1- 4, San Diego, Calif. Abstract 97850 Journal of Hospital Medicine, Volume 7, Suppl 2.
• Washington Manual of Medical Therapeutics
• MKSAP

1. Klion AD. Approach to the patient with suspected hypereosinophilic syndrome. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):47-54. doi: 10.1182/hematology.2022000367. PMID: 36485140; PMCID: PMC9821533.
2. Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. PMID: 28112388.
3. Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010 Jul;126(1):179-81. doi: 10.1016/j.jaci.2010.03.035. PMID: 20639012; PMCID: PMC5781228.
4. Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, Bussmann C, Beglinger C, Schoepfer A, Simon HU. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. 2010 Nov;139(5):1526-37, 1537.e1. doi: 10.1053/j.gastro.2010.07.048. Epub 2010 Aug 1. PMID: 20682320.

References

• Lori Ann Linkins , MD, Antonio L. Dans, MD, et al. Treatment and prevention of Heparin Induced Thrombocytopenia: a systematic review: anti thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2012;141 (2)(suppl): e495S e530s
• MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for anti thrombotic therapy: a systematic review: anti  thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines.  Chest. 2012;141 (2)(suppl):e1S-e23S
• Allyson M. Pishko , MD, Lori Ann Linkins , MD, et al. Diagnosis and Management of Heparin Induced Thrombocytopenia: A Pocket Guide for the clinician 2018
• UpToDate
• MKSAP 19

References

The American Cancer Society. About chronic lymphocytic leukemia. Cancer.org. Accessed 8/30/2022
University of Liverpool Covid-19 Drug Interactions Checker.
A Ralph, B Eperjesiovia, and A Stone, Pleural effusion as a rare presentation of T-Cell Prolymphocytic Leukemia (T-PLL). Pulmonary Manifestations of Systemic Disease. Chest Annual Meeting 2016.
D Catovsky and C Dearden. Treatment of T cell prolymphocytic leukemia. UpToDate.
L Gindi et al. Levels of expression of CD52 in normal and leukemic B and T cells: correleation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22(2):185.
H Kaseb, A Madan, R Killeen, and S Hozayen. T Cell Prolymphocytic Leukemia. StatPearls. Updated May 1 2022: Accessed August 24 2022.
M Gertz. Acute hyperviscosity: syndromes and management. Blood. Volume 32, Number 13, p 1379-1385.
M Lichtman and J Rowe. Hyperleukocytic leukemias: rheological, clinical and therapeutic considerations. Blood. 1982 Aug; 60(2): 279-283
D antwal et al. An unusual presentation of chronic lymphocytic leukemia. Avicenna J Med. 2017 Jul-Sep; 7(3): 133-136
N Singh et al. Leukostasis in chronic lymphocytic leukemia. Am J Case Rep 2020; 21: e924798
B Sing et al. COVID-19-induced hyperleucocytosis in chronic lymphocytic leukaemia. European Journal of Case Reports in Internal Medicine. 2021;8
M Baer et al. Chronic lymphocytic leukemia with hyperleukocytosis. Cancer. 56:2865-2869, 1985.
C Schiffer. Hyperleukocytisis and leukostatis in hematologic malignancies. UpToDate.
CDC Covid-19 Treatment Guidelines: Remdesivir.

References

• Mirrakhimov AE, Voore P, Khan M, Ali AM. Tumor lysis syndrome: A clinical review. World J Crit Care Med. 2015 May 4;4(2):130-8. doi: 10.5492/wjccm.v4.i2.130. PMID: 25938028; PMCID: PMC4411564.
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569. Erratum in: N Engl J Med. 2018 Sep 13;379(11):1094. PMID: 21561350; PMCID: PMC3437249.
• Puri I, Sharma D, Gunturu KS, Ahmed AA. Diagnosis and management of tumor lysis syndrome. J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):269-272. doi: 10.1080/20009666.2020.1761185. PMID: 32850076; PMCID: PMC7426989.
• Washington Manual of Medical Therapeutics 36th Edition
• Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics. 2008;2(1):129-141. doi:10.2147/btt.s1522  Figure 3
• Onco-Nephrology: Tumor Lysis Syndrome August 2012 Clinical Journal of the American Society of Nephrology 7(10):1730-9 Figure 1. https://www.researchgate.net/figure/Cairo-Bishop-classification-of-tumor-lysis-syndrome-in-adults_tbl1_230645601
• UpToDate
• MKSAP19